Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inodiftagene vixteplasmid - Anchiano Therapeutics

Drug Profile

Inodiftagene vixteplasmid - Anchiano Therapeutics

Alternative Names: BC-819; BC-819/PEI; Diphtheria-toxin-A-H19; DTA-H19; DTA-H19/PEI

Latest Information Update: 20 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCancell Therapeutics
  • Developer Anchiano Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer
  • No development reported Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 08 Mar 2019 Anchiano Therapeutics terminates phase-IIb trial in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in Europe, Israel, USA (Intratumoural) (NCT01413087)
  • 18 Dec 2018 Anchiano Therapeutics initiates a phase II Codex trial for Bladder Cancer (Second-line therapy or greater) in USA (NCT03719300)
  • 19 Nov 2018 BioCancell Therapeutics plans to initiate the first of two registrational trials for Bladder cancer before the end of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top